FOSUN PHARMA
复星医药

上海復星醫藥（集團）股份有限公司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. The following sets out the "Announcement in relation to the Progress of Drug Clinical Trials by a Subsidiary" published by Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the "**Company**") on the website of the Shanghai Stock Exchange, for your reference only. The following is a translation of the abovementioned announcement solely for the purpose of providing information. Should there be any discrepancies, the Chinese version will prevail.

By order of the Board
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Wu Yifang
Chairman

Shanghai, the PRC
1 April 2024

As at the date of this announcement, the executive directors of the Company are Mr. Wu Yifang, Mr. Wang Kexin, Ms. Guan Xiaohui and Mr. Wen Deyong; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Yao Fang, Mr. Xu Xiaoliang and Mr. Pan Donghui; and the independent non-executive directors of the Company are Ms. Li Ling, Mr. Tang Guliang, Mr. Wang Quandi and Mr. Yu Tze Shan Hailson.

* *for identification purposes only*

Stock code: 600196 Stock abbreviation: Fosun Pharma No.: Lin 2024-044

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Announcement in relation to the Progress of Drug Clinical Trials by a Subsidiary

The board of directors of the Company and all directors warrant that this announcement does not contain any false information, misleading statement or material omission, and accept legal liability for the truthfulness, accuracy and completeness of the contents herein contained.

I. Overview

Fobeni Healthcom Pharmaceutical Jiangsu Company Limited* (復紅康合醫藥江蘇有限公司), a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (上海復星醫藥(集團)股份有限公司) (the "**Company**" and, together with its subsidiaries/units, the "**Group**", the same applies below), commenced two phase III clinical studies on the combination therapy of OP0595 (Generic name: nacubactam, the "**Investigational New Drug**"), which jointly developed with Meiji Seika Pharma Co., Ltd. (the "**Meiji Seika Pharma**") in the Territory（Mainland China, Hong Kong and Macau）, with cefepime or aztreonam for the treatment of infections due to gram-negative microorganisms in adults with limited therapeutic options in China (excluding Hong Kong, Macau and Taiwan for the purpose of this announcement, the same applies below). The Phase III clinical trials included (1) a Phase III clinical trial evaluating the efficacy and safety of cefepime/Investigational New Drug or aztreonam/Investigational New Drug compared to imipenem/cilastatin for the treatment of complicated urinary tract infections or acute uncomplicated pyelonephritis in adults; and (2) a Phase III clinical trial evaluating the efficacy and safety of cefepime/Investigational New Drug and aztreonam/Investigational New Drug compared to the best available therapy for the treatment of complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital acquired bacterial pneumonia, ventilator-associated bacterial pneumonia and complicated abdominal infections caused by Carbapenem-resistant Enterobacteriaceae.

II. Basic information and research progress of the Investigational New Drug

The Investigational New Drug is a novel beta-lactamase inhibitor for IV use, which is intended for the treatment of infections due to gram-negative microorganisms including Carbapenem-resistant Enterobacteriaceae in adults with limited therapeutic options.

As of the date of this announcement, one Phase I clinical trial in China is on-going, to evaluate the pharmacokinetic profile, safety and tolerability of the Investigational New Drug administered by single and multiple intravenous infusions in health Chinese adults. The on-going two Phase III clinical trials in China are part of the international multicenter clinical trials conducted by Meiji Seika Pharma for the Investigational New Drug.

As of February 2024, the cumulative research and development investment of the Group in the Investigational New Drug at this stage amounted to RMB26.63 million (unaudited).

As at the date of this announcement, the drugs approved for marketing globally for the treatment of infections due to gram-negative microorganisms include imipenem/cilastatin/relebactam, ceftazidime/avibactam, cefiderocol and others. According to the latest IQVIA MIDAS™ data[1], the combined worldwide sales of the related aforementioned drugs approved for marketing globally for the treatment of drug-resistant gram-negative bacteria infections amounted to approximately US$5,047 million in 2022.

III. Risk Reminder

As required by the relevant laws and regulations in China, the Investigational New Drug is subject to a series of clinical studies and approval by the relevant national drug review department in the China before it can be marketed. Based on our research and development experience, there are certain risks underlying the research and development of Investigational New Drug. For example, clinical trials may be terminated due to issues such as safety and/or efficacy.

The research and development and launch of Investigational New Drugs is a long-term task involving various uncertainties. Investors should take note of the investment risks.

Announcement is hereby given.

[1] Provided by IQVIA, a provider of professional information and strategic consulting services for the pharmaceutical and healthcare industry.

Board of directors of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

29 March 2024

* For identification purpose only